← All Scholar Rock Holding CORP filings

Scholar Rock Holding CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SRRK
Scholar Rock Holding CORP
10-K: Scholar Rock Faces FDA Delay for SMA Drug, Secures $350M Financing
Scholar Rock's lead SMA drug, apitegromab, faces regulatory delays due to third-party manufacturing issues, while the company secures new financing and advances its pipeline.
NASDAQ
SRRK
Scholar Rock Holding CORP
10-K: Scholar Rock Announces Positive Phase 3 Results, Submits BLA for Apitegromab in SMA
Scholar Rock's pivotal Phase 3 SAPPHIRE trial achieved its primary endpoint, leading to a BLA submission to the FDA for apitegromab in spinal muscular atrophy.
NASDAQ
SRRK
Scholar Rock Holding CORP
10-K: Scholar Rock Reports 2023 Financial Results and Provides Business Update
Scholar Rock Holding Corporation reports its 2023 financial results, highlighting progress in its clinical programs and strategic focus.